PHAXIAM Therapeutics (PHXM) Stock Price, News & Analysis

Company Overview

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Key Stats

• Today's Range: $3.10 to $3.10
• 50-Day Range: $3.10 to $3.10
• 52-Week Range: $2.50 to $13.00
• Volume: N/A
• Average Volume: 2,472 shs
• Market Capitalization: $10.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PHXM Stock Analysis - Frequently Asked Questions

How have PHXM shares performed this year?

PHAXIAM Therapeutics' stock was trading at $3.10 at the beginning of 2025. Since then, PHXM stock has increased by 0.0% and is now trading at $3.10.
View the best growth stocks for 2025 here.

When did PHAXIAM Therapeutics' stock split?

PHAXIAM Therapeutics shares reverse split on Wednesday, September 20th 2023. The 1-10 reverse split was announced on Wednesday, September 20th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of PHAXIAM Therapeutics?

Shares of PHXM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of PHAXIAM Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PHAXIAM Therapeutics investors own include Salesforce (CRM), AbbVie (ABBV), Bank of America (BAC), Chevron (CVX), Merck & Co., Inc. (MRK), The PNC Financial Services Group (PNC) and AGCO (AGCO).

Company Calendar

• Today: 6/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PHXM
• CIK: 1624422
• Web: erytech.com
• Phone: 33478744438
• Fax: 33-4-78-75-56-29
• Employees: 49
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.23
• Current Ratio: 1.78
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $32.66 million
• Price / Sales: 0.32
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.98 per share
• Price / Book: 0.39

Miscellaneous

• Outstanding Shares: 3,412,000
• Free Float: 3,346,000
• Market Cap: $10.58 million
• Optionable: No Data
• Beta: 2.35